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Despite remarkable improvement in treatment outcomes in pediatric leukemia over the
past several decades, the prognosis for high-risk groups of acute myeloid leukemia (AML)
and acute lymphoblastic leukemia (ALL), as well as for relapsed leukemia, remains poor.
Intensification of chemotherapy regimens for those at highest risk has improved success
rates, but at the cost of significantly increased morbidity and long-term adverse effects.
With the success of imatinib in Philadelphia-chromosome-positive leukemia and all-trans
retinoic acid in acute promyelocytic leukemia, the quest to find additional molecularly tar-
geted therapies has generated much excitement over recent years. Another such possible
target in pediatric acute leukemia is FMS-like tyrosine kinase 3 (FLT3). FLT3 aberrations
are among the most frequently identified transforming events in AML, and have significant
clinical implications in both high-risk pediatric AML and in certain high-risk groups of pedi-
atric ALL.Therefore, the successful targeting of FLT3 has tremendous potential to improve
outcomes in these subsets of patients. This article will give an overview of the molecular
function and signaling of the FLT3 receptor, as well as its pathogenic role in leukemia. We
review the discovery of targeting FLT3, discuss currently available FLT3 inhibitors in pedi-
atric leukemia and results of clinical trials to date, and finally, consider the future promise
and challenges of FLT3 inhibitor therapy.
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INTRODUCTION
Remarkable strides have been made in the past several decades
in the treatment success rates of childhood acute lymphoblas-
tic leukemia (ALL), with 5-year survival rates now approaching
90% (1). However, up to 20% of children will be refractory
to treatment, or relapse following treatment, and the event-free
survival (EFS) rate for these patients remains poor. In acute
myeloid leukemia (AML), although the majority of children will
achieve an initial remission with conventional chemotherapy,
<60% will be long-term survivors (2). Furthermore, the inten-
sification of treatment regimens required to achieve the highest
possible survival rates for poor risk leukemia has been pushed to
the limit of tolerance, highlighting the need for effective targeted
therapies (3).
Two successful examples of targeted therapies in pediatric
leukemia include tyrosine kinase inhibitors in BCR-ABL-positive
ALL (4) and all-trans retinoic acid (ATRA) in acute promyelo-
cytic leukemia (APML) with the PML–RARα fusion (5). FMS-like
tyrosine kinase 3 (FLT3) represents another attractive target, given
its overexpression on the majority of leukemia cells and the high
rate of FLT3 mutations in human leukemia. Since the receptor was
first described over 20 years ago, targeting FLT3 therapeutically
has generated much excitement. The first clinical trials with FLT3
inhibitors took place 10 years ago,and though some inhibitors have
shown good promise in effective targeting, they also presented
several clinical challenges. This is underscored by the fact that
no FLT3 inhibitors have been FDA-approved for the treatment of
leukemia to date. This review will summarize the biology of FLT3
in leukemia, and discuss the benefits and hindrances associated
with FLT3 inhibitor therapy.
BIOLOGY OF THE FLT3 RECEPTOR
MOLECULAR STRUCTURE AND NORMAL TISSUE EXPRESSION OF FLT3
FMS-like tyrosine kinase 3 belongs to the class III receptor tyrosine
kinase (RTK) family, along with KIT, FMS, and platelet-derived
growth factor receptor (PDGFR). As such, FLT3 contains an extra-
cellular domain made up of five immunoglobulin-like regions at
the amino terminus, a single transmembrane region, an intracel-
lular juxtamembrane domain (JMD), and two kinase domains at
the carboxyl terminus, separated by a kinase insert region (6, 7)
(Figure 1). FLT3 is expressed in normal human bone marrow
(BM), particularly in CD34+ hematopoietic stem and early prog-
enitor cells (6, 8) and in dendritic cell progenitors (9). FLT3 is also
expressed in human brain, placenta, and testis (7, 10), though its
function in these tissues remains unclear.
NORMAL RECEPTOR FUNCTION
FMS-like tyrosine kinase 3 signaling is central to the develop-
ment of hematopoietic stem cells, B-cell progenitors, dendritic cell
progenitors, and natural killer (NK) cells. This was first demon-
strated through studying the targeted disruption of either FLT3
or its ligand, FLT3 ligand (FL), in CD34+ cells or in mice (8,
11, 12). Mice homozygous for a deletion of FLT3 mature into
normal adults, but BM evaluation reveals deficiencies in B-cell
progenitors, and transplantation studies show deficiencies in T-
lymphocytes and myeloid cells (11). In colony-forming assays,
human CD34+FLT3high BM cells give rise to colony-forming
unit granulocyte-monocyte (CFU-GM) colonies and are pre-
dominantly in G1 phase of cell cycle, whereas CD34+FLT3low
cells give rise to erythroid colonies and are predominantly in
G0 phase (13). Together, these data reveal the significant role of
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FIGURE 1 | Schematic illustrating the structure and function of FLT3, including the sites of the most common activating mutations.
FLT3 in both differentiation and proliferation of hematopoietic
progenitor cells.
FLT3 ligand
FMS-like tyrosine kinase 3 ligand was described shortly after the
discovery of the FLT3 receptor (14, 15). FL is expressed in many
different human tissues, though its co-expression with FLT3 is
limited to the gonads and hematopoietic tissue (16). FL is also
produced by BM stroma, an important source of cytokines and
growth factors responsible for the proliferation and differentia-
tion of hematopoietic progenitor cells (17). It is found in both
soluble and membrane-bound forms, and selectively stimulates
the proliferation and colony formation of CD34+ progenitor cells
(16). Upon binding to FLT3, FL induces dimerization of the recep-
tor and auto-phosphorylation of tyrosine residues in the kinase
domains, leading to downstream activation and phosphorylation
of protein substrates (18).
FLT3 signaling pathways
Upon stimulation with FL, FLT3 activation results in the down-
stream activation of multiple signaling pathways, including the
Ras/Raf and the phosphatidylinositol 3′ kinase (PI3K) pathways.
Many important signaling and adaptor proteins are involved,
including signal transducer and activator of transcription 5
(STAT5), phospholipase Cγ (PLC-γ), CBL, growth factor receptor-
bound protein 2 (Grb2), SHC, Src-homology 2 containing pro-
tein tyrosine phosphate (SHP-2), Src-homology 2 containing
inositol phosphatase (SHIP), mitogen activated protein kinase
(MAPK), and extracellular-signal regulated kinase (ERK1/2) (19–
24). This cascade of phosphorylation and activation ultimately
results in increased cell proliferation, decreased cell apoptosis, and
inhibition of cell differentiation.
FLT3 ABERRANCIES IN LEUKEMIA
FMS-like tyrosine kinase 3 is aberrantly expressed in all precursor
B-cell (pre-B) ALL and nearly all AML primary leukemia sam-
ples, as well as a fraction of T-cell ALL patient samples (25, 26).
FLT3 is also expressed in the majority of pre-B ALL and AML cell
lines (27–29). FLT3 is expressed in most chronic myeloid leukemia
(CML) blast crisis patient samples, irrespective of phenotype, as
well as in several chronic lymphocytic leukemia (CLL) samples
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(26). Importantly, FLT3 is expressed on leukemia blasts regardless
of CD34 expression, whereas FLT3 expression is limited to the
CD34+ population in normal human BM (26, 27). This pattern of
FLT3 expression in leukemia is in contrast to KIT and FMS expres-
sion, which are typically restricted to myeloid leukemia (25). FL
is expressed in most leukemia cell lines from all cell lineages, and
in one study, 40 of 110 human leukemia cell lines expressed both
FL and FLT3 (27). Another study showed that wild-type FLT3 is
constitutively activated in two-thirds of AML patient samples and
in 4 of 13 leukemia cell lines tested (30). These cells co-expressed
FLT3 and FL, suggesting a role for autocrine signaling.
FLT3-ACTIVATING MUTATIONS
Activating mutations of FLT3 were first described in AML in
1996. There are two broad categories: internal tandem duplica-
tions (ITD) and point mutations in the tyrosine kinase domain
(TKD). In pediatric AML, activating mutations occur in 20–
25% of patients, with roughly two-thirds of these harboring
ITD mutations, and the remaining one-third with TKD point
mutations.
ITD mutations
Internal tandem duplications mutations in the JMD of the FLT3
gene were first described in adult patients with AML, and even
in that small cohort of patients, it appeared that these mutations
conferred a poor prognosis (31). A region of the JMD coding
sequence is replicated in a direct head-to-tail orientation, creating
the ITD. As initially described, ITDs vary in length and location,
but tend to occur in replicates of three nucleotides, maintaining an
intact reading frame and not affecting other regions of the gene,
including the kinase domains (31–33). ITD mutations result in
ligand-independent dimerization of the FLT3 receptor, constitu-
tive phosphorylation, and activation of the kinase domains (32, 34,
35). It is proposed that ITD mutations occur as DNA replication
errors, and are selected due to the resulting growth advantage (32).
In both AML and normal hematopoiesis, self-renewal capac-
ity is limited to the immature CD34+ CD38− cell population
(36). There is increasing evidence that FLT3-ITD has activity in
hematopoietic stem cells (37), as demonstrated by the presence of
ITD in the CD34+CD38− leukemia-initiating cell (LIC) popula-
tion, and confirmation of the ITD mutation in these successfully
engrafted LICs in a murine transplant model (38). In BM cells
from a knock-in heterozygous FLT3-ITD-mutant mouse model,
FLT3 expression and signaling was present within the long-term
hematopoietic stem cell (LT-HSC) compartment, and importantly,
the ITD mutation conferred a proliferative effect on this nor-
mally quiescent population, depleting the LT-HSC compartment
(39). Interestingly, this effect was reversed with the FLT3 inhibitor
sorafenib, repleting the LT-HSC population and returning these
cells to a quiescent state.
Clinical relevance of ITDmutations in human leukemia. Inter-
nal tandem duplications mutations are a common somatic muta-
tion in adult AML, occurring in approximately 20–35% of patients
(31, 40–43). ITD mutations occur less frequently in pediatric AML,
found in approximately 5–15% of newly diagnosed patients (44–
46). The presence of an FLT3-ITD mutation in pediatric AML is
associated with higher WBC counts at presentation, older age,
higher rates of induction failure, and significantly worse sur-
vival. In a retrospective study of de novo AML pediatric patients
enrolled in Children’s Cancer Group study (CCG)-2891, mul-
tivariate analysis identified ITD mutations as an independent
prognostic factor for poor outcome in pediatric AML. This study
revealed 8-year overall survival (OS) and EFS rates of 13 and 7%,
respectively, for children with ITD mutations versus OS of 50%
and EFS of 44% for children without ITD mutations (46). Fol-
lowing these results, the risk stratification of pediatric patients
with ITD mutations has been a dynamic process. One pediatric
study showed that the presence of FLT3-ITD mutations in the
more primitive CD34+ CD33− cell population was heterogeneous
(present in approximately 80% of ITD-positive AML patients),
and conferred a worse prognosis compared to patients in which
the ITD mutations was only present in CD34+ CD33+ cells (47).
Furthermore, in a large retrospective study of adults with AML
characterizing patients with FLT3 mutations, adults with higher
ITD allelic ratios had significantly shorter overall and disease-free
survival (42). A subsequent retrospective study of children with de
novo AML, enrolled on studies CCG-2941 and -2961, determined
that an ITD allelic ratio of 0.4 or higher identified the highest
risk group with the worse prognosis, whereas children with allelic
ratios<0.4 had similar outcomes as children with wild-type FLT3
(48). Therefore, the current Children’s Oncology Group (COG)
phase 3 clinical trial for AML risk-stratifies patients with FLT3-ITD
allelic ratios >0.4 into the high-risk group, regardless of having
any other low risk factor. These patients will receive more inten-
sive chemotherapy, including the FLT3 inhibitor sorafenib (further
discussed below), as well as hematopoietic stem cell transplanta-
tion (HSCT) in first remission, in an attempt to improve outcomes
for this subset of patients.
Additionally, loss of the FLT3-wild-type allele and resultant
copy number-neutral ITD homozygosity has been demonstrated
in AML, particularly at disease progression, and is associated with
a worse prognosis (49–51). Copy-neutral loss of heterozygosity
(CN-LOH) is a common event in both solid and hematologic
malignancies, and can lead to either inactivation of a tumor
suppressor gene or enhanced activity of an oncogene. Acquired
CN-LOH or uniparental disomy, is seen in leukemia with loss of
the normal allele and duplication of the mutant allele (52–55),
such as seen with FLT3-ITD mutations.
Although ITD mutations were first described in the JMD, it was
later discovered that ITD mutations occur up to 30% of the time
in non-JMD regions of the gene (56, 57). In fact, in a large review
of 241 FLT3-ITD AML patients, those with an ITD in the beta-1
sheet of the TKD had a significantly inferior remission rate, relapse
free survival, and OS compared to those with an ITD located in
the JMD (57). This suggests relevance to identifying not only the
presence and allelic burden of FLT3-ITD but also the ITD location.
There are conflicting reports as to whether the length of the
ITD carries prognostic significance in AML. In one retrospective
review of adult data, patients harboring an ITD >40 base pairs
had an inferior 5-year OS of 13% compared to 26% in those with
an ITD <40 base pairs, and 21% in patient with no ITD muta-
tion (58). This group hypothesized that longer ITDs may lead to
increased disruption of the auto-inhibitory function of the JMD.
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However, another group demonstrated opposing results, showing
inferior survival in patients with shorter ITDs, using a cutoff of
70 base pairs (59). Prospective, larger studies are likely needed to
determine whether ITD size truly affects prognosis.
Finally, a recent report evaluated the prevalence and prognos-
tic significance of FLT3 mutations in childhood APML. It is well
known that FLT3 mutations are common in APML, and the block
in differentiation conferred by t(15;17) likely cooperates with the
proliferative advantage of FLT3 mutations. In 104 pediatric APML
patients, 40% had either FLT3-ITD or a TKD point mutation.
These patients had higher WBC counts at diagnosis and increased
rates of induction deaths when treated with ATRA alone (60). No
difference in outcomes with FLT3 mutations were demonstrated
post-induction therapy. It is unclear if the increased induction
deaths were due to the higher WBC count or FLT3 mutations;
however, it is hypothesized that the presence of a FLT3 mutation
is causative of the higher WBC counts in these patients. Gene-
expression profiling in FLT3-mutant APML showed up-regulation
of genes involved in proliferation, coagulation, and inflammation
(61). This suggests a role for evaluating FLT3 mutation status
in APML and consideration of early FLT3 inhibitor therapy in
FLT3-mutant APML patients.
Mechanism of ITDmutation-induced leukemogenesis andmodel
systems. Multiple signaling pathways are implicated in aberrant
FLT3 activation in cells. The JMD of FLT3 contains auto-inhibitory
function and maintains the kinase in an inactive conformation
(62). The disruption of this region by an ITD results in consti-
tutive activation of the FLT3 receptor (63). Activation of FLT3
results in the phosphorylation of proteins such as Gab2, SHP-2,
and CBL, forming a complex that interacts with the p85 subunit of
PI3K, thereby activating the anti-apoptotic PI3K pathway (20, 23).
Serine/threonine protein kinase B (AKT) is shown to be phospho-
rylated and constitutively activated in 32D cells, which have been
stably transfected with ITD (64).
The proliferative Ras/MAPK pathway is also activated with
FLT3 signaling. Ba/F3 cells transfected with wild-type human FLT3
and stimulated with FL demonstrate transient activation of MAPK
and phosphorylation of ERK1/2 (21). MEK inhibition reverses this
activation and also inhibits the proliferative effect of FL on these
cells. Both 32D and Ba/F3 cells transfected with FLT3-ITD alone
show activation of MAPK (64, 65). Finally, MAPK is activated in
primary AML blasts (65, 66).
STAT5 is involved in the regulation of self-renewal and differ-
entiation of hematopoietic progenitor cells (67), and its aberrant
activation has been demonstrated in human leukemia (68). STAT5
is constitutively phosphorylated and activated in cell lines trans-
fected with FLT3-ITD mutations, as well as leukemia cell lines
and primary AML blasts containing endogenous ITD mutations,
but STAT5 is not activated in cells with wild-type FLT3, despite
stimulation with FL (64, 65, 69, 70). FLT3-ITD-induced STAT5
activation was found to be independent of Src or Jak kinases in
cell lines deficient for these kinases, and in vitro assays revealed
that STAT5 is a direct target of FLT3 (71).
Yet, another potential mechanism of ITD mutations in leuke-
mogenesis is the decreased expression of SHP-1, a phosphatase
responsible for the down-regulation of multiple growth factor
and cytokine signaling pathways. TF1 cells transfected with ITD
induced a threefold decrease in SHP-1 activity (72). Decreased
expression of SHP-1 results in increased proliferation in these cells.
Also, in vitro treatment of FLT3-ITD cell lines and primary AML
patient samples with an FLT3 inhibitor resulted in up-regulation
of SHP-1 expression. Taken together, these data implicate SHP-1
as a tumor suppressor that has significantly decreased activity in
ITD-positive AML (72).
Finally, FLT3-ITD also contributes to a block in cell differenti-
ation. 32D cells transfected with ITD do not undergo granulocyte
differentiation in response to granulocyte colony stimulating-
factor (G-CSF) (73). Subsequent investigation showed that the
expression levels of C/EBPα and PU.1, both important modula-
tors of myeloid differentiation, are repressed in the presence of
FLT3-ITD (74). Treatment of these cells with an FLT3 inhibitor
restored expression of these proteins and resulted in myeloid
differentiation.
While FLT3-ITD has certainly been demonstrated as a trans-
forming lesion in multiple cell models and clearly contributes
strongly to leukemogenesis, it is not sufficient to fully transform
primary hematopoietic cells or generate leukemia in mouse mod-
els. FLT3-ITD expression confers cytokine-independent growth in
32D and Ba/F3 cell lines (64, 65), and induction of the signaling
pathways discussed above. Mice injected with these transformed
cell lines rapidly developed a leukemia-like illness (64, 66), but
transplantation of primary BM cells retrovirally transduced with
FLT3-ITD causes only a myeloproliferative disease (MPD) and
not leukemia (75). Knock-in of heterozygous mutant ITD into
murine FLT3 (FLT3+/ITD) causes a fatal MPD characterized by
splenomegaly, leukocytosis, and myeloid expansion, but not frank
leukemia (76). Consistent with cell models, these mice demon-
strate expansion of dendritic cells and a block in B-cell devel-
opment, caused by inefficient double strand break repair by non-
homologous end joining and failure of proper VDJ rearrangement
in pro-B cells (77).
The heterozygous FLT3-ITD mutation does, however,
cooperate with other molecular lesions in mouse models to gen-
erate both myeloid and lymphoid leukemia, such as MLL-AF9
(78), mutant C/EBPα (79), NUP98–HOXD13D (NHD13) fusion
(80), and mutant nucleophosmin (NPMc+) (81), in agreement
with accumulating evidence that leukemogenesis is a process
that requires multiple genetic or epigenetic “hits.” Interestingly,
a mouse model of homozygous FLT3-ITD mirrored the increased
disease severity of CN-LOH seen in human malignancy with
some homozygous mice developing spontaneous leukemia (77).
Another group found similar results with homozygous FLT3-ITD
knock-in mice, and by crossing these mice with FL knockout mice,
also demonstrated that the homozygous FLT3-ITD phenotype is
FL-independent, in contrast to the heterozygous FLT3-ITD mice,
which had a milder phenotype in the absence of FL (82). These
data suggest that ITD gene “dosage” is probably most impor-
tant in LOH, but that loss of the wild-type allele also plays a
functional role. This is in agreement with in vitro experiments
showing enhanced FLT3 signaling in response to FL in FLT3-ITD-
expressing cell lines, but no consistent effects of FL on STAT5
phosphorylation or other signaling pathways in primary AML
blasts homozygous for ITD (83).
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Tyrosine kinase domain point mutations
Point mutations in the activation loop of the TKD of FLT3 were
first described in de novo human leukemia in 2001 (84, 85). This
area of the gene was interrogated for mutations because the corre-
sponding domain in KIT was reported to harbor oncogenic acti-
vating point mutations (86). The first TKD mutations described
involved aspartic acid residue D835, which is equivalent to D816
mutations in KIT, and less commonly, isoleucine I836. The D835
mutation is a missense mutation and confers a change in amino
acid to tyrosine, histidine, valine, glutamic acid, or asparagine.
In these newly diagnosed adult AML patients, TKD mutations
occurred independently of ITD mutations (85).
Clinical relevance of TKDmutations in human leukemia. Tyro-
sine kinase domain mutations are less common than ITD muta-
tions and do not appear to carry the same prognostic significance
in leukemia. In fact, TKD and ITD mutations demonstrated dif-
fering gene-expression profiles in newly diagnosed pediatric AML
patients (87). In large retrospective studies, TKD mutations were
present in ~7% of both adult and pediatric de novo AML (42,
48, 85). In contrast to patients with ITD mutations, patients with
D835 TKD mutations did not have elevated WBC counts com-
pared to those with wild-type FLT3 (48, 85, 88). In a large adult
study, 17 of 979 (1.7%) AML patients were positive for both ITD
and TKD mutations, and 4 of 10 of these harbored the mutations
on the same allele (42). In one pediatric study, 35% of patients
with TKD-mutant AML also harbored an 11q23/MLL rearrange-
ment (MLL-r) (26% had MLL-AF9) in comparison to 24% of
FLT3-wild-type and only 2% of ITD-mutant AML patients with
MLL-r (48).
Interestingly, in pediatric pre-B ALL, FLT3-TKD mutations are
not infrequently associated with MLL-r. In 30 MLL patient samples
tested, 5 (16%) had mutations in the activation loop of TKD, and
the residues involved were the same as demonstrated in AML, e.g.,
D835 (89). This group demonstrated that these TKD mutations
resulted in constitutive activation of FLT3, an effect that could
be reversed with a FLT3 small-molecule inhibitor. This was the
first suggestion of clinically relevant TKD mutations in ALL, and
implied a role for FLT3 inhibition in this subset of MLL-r patients.
FLT3 mutations were also detected in 20–25% of hyperdiploid
(>50 chromosomes or DNA index >1.14) diagnostic pre-B ALL
samples, and were associated with high levels of FLT3 expres-
sion (90, 91). In these small cohorts of hyperdiploid patients, it is
unclear if FLT3 mutations affect prognosis, and larger prospective
studies would need to determine this. These data nevertheless sup-
port a potential role for FLT3 inhibitors in this additional cohort
of patients.
Arguably, the most clinically relevant role of FLT3-TKD muta-
tions in leukemia is the development of a secondary point muta-
tion detected at relapse, as a mechanism of resistance in patients
with a pre-existing ITD mutation and after FLT3 inhibitor therapy.
This important issue is discussed later in this review.
Mechanism of TKD mutation-induced leukemogenesis and
model systems. In wild-type FLT3, the activation loop of the TKD
normally maintains a “closed” conformation, preventing ATP and
proteins from binding (63). The presence of a TKD mutation in
this area is thought to open the activation loop, allowing for con-
stitutive activation of the receptor. Phenylalanine substitutions for
tyrosine residues in the kinase domain in a TKD-mutant mouse
model revealed three critical residues involved in stabilizing the
active conformation of the activation loop, one of which is the
site of auto-phosphorylation in TKD mutants (92). Functional
studies in Cos7 and 32D cells demonstrate that D835 TKD muta-
tions result in auto-phosphorylation and constitutive activation
of FLT3 independent of FL, in a similar manner to ITD mutations.
D835 mutations also confer cytokine independence in 32D cells
(85), further evidence of their gain of function, and transform-
ing capability. Yamaguchi et al. also reported a robust increase in
IL-3-independent proliferation in 32D cells expressing both TKD
mutations and MLL-AF4 (93).
A murine BM transplant model using retroviral transduc-
tion compared disease phenotypes of FLT3-ITD and FLT3-TKD
mutations in vivo, and surprisingly, TKD mutations caused an
oligoclonal lymphoid disorder (both B- and T-lymphoid) com-
pared to MPD seen with ITD mutations (94). The disease latency
was longer than with ITD mutations, and mice with TKD muta-
tions did not develop leukocytosis. Some myeloid expansion was
seen in TKD-mutant BM, although the primary disease pheno-
type was lymphoid. In transfected Ba/F3 and 32D cells, AKT and
ERK1/2 were similarly phosphorylated with ITD and TKD muta-
tions, but STAT5 was significantly more phosphorylated with the
ITD mutation in both cell lines, and in transduced BM cells (94).
In a recent report, a knock-in mouse model heterozygous for the
D835Y mutation was generated, and shown to survive signifi-
cantly longer than heterozygous FLT3-ITD knock-in mice (95).
In contrast to the first model, in which FLT3 retroviral trans-
duction likely resulted in overexpression of FLT3, the majority
of these knock-in mice did develop myeloproliferative neoplasms
(MPN), albeit with a less aggressive phenotype than the FLT3-ITD
mice. Also, whereas a significant block in B-cell development and
drastic reduction in the LT-HSC compartment were demonstrated
in the FLT3-ITD mice, neither was observed in the FLT3-D835Y
mice. Consistent with the other mouse model, STAT5 was sig-
nificantly more phosphorylated in FLT3-ITD mice compared to
FLT3-D835Y mice (95), suggesting that differential STAT5 signal-
ing may explain the different phenotypes seen between FLT3-TKD
and FLT3-ITD leukemia.
FLT3 OVEREXPRESSION IN LEUKEMIA
Gene-expression profiling of patients samples comparing pre-B
ALL with MLL-r, pre-B ALL without MLL-r, and AML demon-
strated that MLL-r leukemia contains a unique signature (96).
MLL-r leukemia samples generally expressed high levels of genes
associated with hematopoietic progenitor cells, suggesting that
MLL is arrested at an earlier stage of development. Armstrong et al.
found that the most consistently and impressively overexpressed
gene in MLL-r leukemia is FLT3.
MLL-r infant ALL
Expanding on their gene-expression profiling data, Armstrong
et al. found that overexpression of wild-type FLT3 is an acti-
vating lesion in SEMK2, a t(4;11) MLL-r pre-B ALL cell line
(89). Strikingly, FLT3 is basally phosphorylated and constitutively
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activated in this cell line, to an even higher extent than in the
AML cell line MV4;11, which contains an FLT3-ITD mutation
as well as t(4;11). This was in contrast to two pre-B ALL cell
lines without MLL-r or FLT3 overexpression, and the pre-B ALL
cell line RS4;11 which contains t(4;11) but does not demon-
strate FLT3 overexpression. FLT3 overexpression in SEMK2 cells
is due to intra-chromosomal amplification of the gene locus,
with each cell containing one to two amplicons of 10 copies of
the gene. An FLT3 small-molecule inhibitor demonstrated selec-
tive cytotoxicity and reversal of FLT3 activation in SEMK2 and
MV4;11 cells, and showed anti-tumor effect in vivo in a leukemia
mouse model engrafted with SEMK2, but not with RS4;11 cells
(89). It was then shown that CEP-701 (lestaurtinib), a small-
molecule FLT3 inhibitor, is selectively cytotoxic in infant ALL
patient samples with MLL-r and FLT3 overexpression, as well as in
FLT3-overexpressing hyperdiploid ALL (97, 98). Lestaurtinib has
also been shown to reverse FLT3 auto-phosphorylation in FLT3-
overexpressing ALL patient samples (97). Importantly, subsequent
studies of infant ALL patients revealed a worse overall prognosis
with high levels of FLT3 expression in MLL-r leukemia (99, 100).
These data serve as the pre-clinical rationale for FLT3 inhibition
in FLT3-overexpressing MLL-r ALL in infant leukemia.
Hyperdiploid ALL
Gene-expression analysis of a large number of diagnostic pediatric
ALL cases also demonstrated overexpression of FLT3 in hyper-
diploid (>50 chromosomes) samples (101). To our knowledge,
there is no pre-clinical or clinical study of FLT3 inhibition in hyper-
diploid ALL, possibly due to the relatively good clinical outcomes
of these patients with traditional chemotherapy.
Mechanism of FLT3 overexpression-induced leukemogenesis and
model systems
Constitutive FLT3 signaling and the leukemogenic role of FLT3
overexpression in these subsets of ALL is likely caused either
by concomitant FLT3-TKD mutations, or the co-expression and
autocrine signaling of FL. In model systems, Ba/F3 cells overex-
pressing wild-type FLT3 did not become cytokine-independent, in
contrast to FLT3-mutant-expressing cells. However, FLT3 overex-
pressing Ba/F3 cells engrafted into Balb/c mice did cause leukemia,
which may have been secondary to murine FL expression in
this model (69). The transplantation of Balb/c mice with FL-
expressing BM also caused leukemia, albeit with a longer latency
(102), again suggesting an autocrine or paracrine role of FL in
these models.
FLT3-TARGETED THERAPY
DISCOVERY, PRE-CLINICAL EVIDENCE AND PHARMACODYNAMICS
ASSESSMENT OF FLT3 INHIBITORS
First small-molecule inhibitors: in vitro proof of principle
Similar to the small-molecule tyrosine kinase inhibitor imatinib,
FLT3 inhibitors act by competitively binding to the ATP-binding
site. The first FLT3 small-molecule kinase inhibitors reported
were AG1295 and AG1296, which were selectively cytotoxic to
cell lines transfected with FLT3-ITD and primary patient samples
with ITD mutations, and demonstrated inhibition of downstream
FLT3 signaling in vitro (103, 104). Despite achievable IC50’s in
the nanomolar range, these initial inhibitors are not soluble and
therefore not biologically available.
CEP-701 (lestaurtinib) is an orally available indolocarbazole
derivative with activity against multiple kinase receptors. It
was discovered through a small-molecule inhibitor library
screen, and was subsequently found to selectively inhibit auto-
phosphorylation of constitutively active FLT3 in vitro, as well
as prolong survival of an FLT3-ITD mouse model in vivo (66).
Furthermore, lestaurtinib was selectively cytotoxic to FLT3-ITD
primary pediatric AML samples compared to FLT3-wild-type or
FLT3-TKD-mutant patient samples (105). Aberrant overexpres-
sion of wild-type FLT3 in infant MLL-r and hyperdiploid ALL
can cause constitutive FLT3 activation; therefore, lestaurtinib was
next investigated in cell lines and primary patient samples with
these lesions. Selective cytotoxicity, inhibition of FLT3 phospho-
rylation, and overall suppression of FLT3-dependent survival were
demonstrated with lestaurtinib (97). These pre-clinical data were
the supporting evidence to investigate lestaurtinib in clinical trials.
Similar to the lestaurtinib story, others investigated PKC412, a
small-molecule developed as a protein kinase C inhibitor, but was
found to have inhibitory activity against multiple class III RTK,
including PDGFR, VEGFR, and FLT3 (106). PKC412 (midostau-
rin) inhibits the proliferation of transformed cell lines transfected
with activating mutations of FLT3, and shows clinical activity in
mice with FLT3-induced MPD (75, 106).
Sequential delivery of FLT3 inhibitors and chemotherapy
Incorporation of FLT3 inhibitors into existing chemotherapy reg-
imens was studied pre-clinically, first in FLT3-ITD-expressing cell
lines and primary patient AML blasts. In vitro, pre-treatment
with lestaurtinib followed by chemotherapy agents is antagonis-
tic, whereas simultaneous therapy or treatment with lestaurtinib
after chemotherapy has a synergistic cytotoxic effect (107). FLT3
inhibitors arrest FLT3-activated cells in G1 phase of cell cycle,
rendering these cells insensitive to drugs such as cytarabine and
etoposide that exert their cytotoxic effects on cells in active S phase.
Surprisingly, AML cells with either ITD or wild-type FLT3 showed
synergistic cytotoxicity with lestaurtinib and daunorubicin. This
effect is likely due to the competitive binding of these drugs to
the same plasma protein, increasing their free concentrations,
which could potentially increase systemic toxicity of daunoru-
bicin. Treating cells with chemotherapy first, followed by lestau-
rtinib, surmounts both of these undesirable combination effects.
Similar combination experiments in infant MLL-r ALL cells over-
expressing wild-type FLT3 were performed, and again synergy was
observed using chemotherapy first, followed by lestaurtinib (108).
These models provided invaluable guidance moving forward with
FLT3 inhibitors in clinical trials.
Development of correlative assay to determine efficacy (PIA)
The hypothesis of kinase inhibitors in malignancies is that inhibi-
tion of the kinase receptor signaling will result in anti-tumor effect
and concomitant clinical response. However, acquiring tissue to
compare signaling changes before and after therapy is challeng-
ing. Additionally, plasma drug concentration does not necessarily
reflect therapeutic efficacy, since variances in plasma protein bind-
ing affects the level of free/active drug. For these reasons, a useful
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surrogate in vitro assay was developed to assess the efficacy of FLT3
inhibition in patients. A plasma inhibitory assay (PIA) utilizes
an FLT3-ITD transfected cell line, TF1-ITD, mixed with patient
plasma at various time points during treatment, to measure levels
of FLT3 phosphorylation (109). This method reliably correlated
with patient responses to treatment. In a phase 1 clinical trial with
lestaurtinib, a PIA of 85% or greater correlated with patient clin-
ical response to drug and reflects an approximate threshold for
FLT3 inhibition in vivo (110).
FLT3 INHIBITORS IN LEUKEMIA
This section will summarize the best-characterized FLT3 inhibitors
in use in pediatric leukemia, and discuss some relevant adult
clinical trial data. A summary of recently completed or ongoing
pediatric clinical trials with FLT3 inhibitors, along with the NCT
identifying numbers, is shown in Table 1.
CEP-701/lestaurtinib
CEP-701/lestaurtinib in adult leukemia. The first use of
FLT3 inhibitors in leukemia patients was a small phase 1/2
trial of lestaurtinib monotherapy in adult patients with heavily
pretreated, refractory/relapsed AML. Five of 14 patients achieved
some clinical response, with a significant decrease in mar-
row or circulating peripheral blasts, and little observed tox-
icity. PIAs were performed on patient plasma as described
above, and demonstrated inhibition of FLT3 activity down to
a target level of 10–15% in 8 of 14 evaluable patients; 5 of
these were the patients with clinical responses. Interestingly,
the other patient samples with good FLT3 inhibition did not
demonstrate cytotoxicity in vitro or clinical response, suggest-
ing a resistant phenotype. Clinical responses lasted 2 weeks to
3 months (110).
A phase 2 study of lestaurtinib followed, in older adults with
newly diagnosed AML who were unsuitable candidates for con-
ventional chemotherapy (113). Drug was again generally well
tolerated with mild GI toxicities. Two of 29 patients had grade 4
thrombocytopenia, and one died from a CNS hemorrhage. Three
of 5 patients with mutant FLT3 and 5 of 22 patients with wild-type
FLT3 experienced some clinical response with decreased blasts,
which again correlated with the degree of FLT3 inhibition by
PIA data. Again, responses with monotherapy were short-lived,
generally only sustained for several weeks.
Table 1 | Pediatric clinical trials with FLT3 inhibitors: recently completed or ongoing studies.
Trial identifier Phase Status Patients Drug(s) Results
NCT00469859
COG
AAML06P1
1/2 Completed Relapsed AML Lestaurtinib
(CEP-701)
Cytarabine
Idarubicin
Not published
NCT00557193
COG-AALL0631
3 Completed Newly diagnosed ALL
Infants <12 m
Lestaurtinib
(CEP-701)
Chemotherapy
(modified P9407)
Not published
NCT00866281 1/2 Recruiting MLL-r infant ALL
FLT3-mutant AML
Midostaurin
(PKC412)
N/A
NCT01411267
TACL 2009-004
1 Completed Relapsed/refractory ALL
or AML
Quizartinib (AC220)
Cytarabine
Etoposide
Methotrexate
Not published; Abstract
presented at ASH 2013
NCT00908167
St. Jude
RELHEM
1 Recruiting Relapsed/refractory ALL
or AML
Sorafenib
Cytarabine
Clofarabine
N/A; although pilot
cohort data published:
Inaba et al. (111)
NCT00665990
St. Jude
ANGIO1
1 Recruiting Refractory ALL, AML or
solid tumors (solid tumor
portion completed)
Sorafenib
Bevacizumab
Low dose-cytoxan
N/A
NCT01371981
COG AAML1031
3 Recruiting Newly diagnosed AML Sorafenib
Bortezomib
Chemotherapy (ADE
or ADE/MA based)
N/A
NCT01445080 1 Completed Refractory ALL, AML or
solid tumors
Sorafenib Published; Widemann
et al. (112)
Trial information from www.clinicaltrials.gov referenced July, 2014.
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A randomized phase 2 study of salvage chemotherapy in com-
bination with lestaurtinib was completed in adult patients with
FLT3-mutant AML in first relapse (114). There was no difference
in OS between the two arms, but importantly, only 58% of patients
treated with lestaurtinib achieved FLT3 inhibition down to target
levels, and only 27% sustained FLT3 inhibition. FLT3 inhibition
correlated well with drug response, whereas plasma drug concen-
tration did not correlate well with response. These results validate
the importance of the correlative laboratory studies in determining
patient response to FLT3 inhibitors.
CEP-701/lestaurtinib in pediatric leukemia. Based on the pre-
clinical data in pediatric leukemia with either activating FLT3
mutations or overexpression, lestaurtinib was moved into pedi-
atric trials. In 2007, the COG opened a phase 1/2 pilot study of
lestaurtinib in relapsed/refractory AML patients with FLT3 muta-
tions. Dose level 1 was 50 mg/m2 and dose level 2 was 62.5 mg/m2,
given orally, in combination with idarubicin and cytarabine. Based
on the drug-sequence pre-clinical data, chemotherapy was given
on days 1–4, and lestaurtinib given on days 5–28. The study com-
pleted accrual in 2010, and data are not yet published. Primary
outcomes studied were safety/tolerability and>80% inhibition of
FLT3 phosphorylation in the majority of patients at trough time
points.
A phase 3, randomized COG trial with lestaurtinib, in com-
bination with standard chemotherapy, opened in 2008 for newly
diagnosed infant ALL (COG-AALL0631). The study has recently
completed, and results are pending. Intermediate risk (MLL-r
and >90 days old) and high-risk patients (MLL-r and <90 days
old) were randomized to receive lestaurtinib after induction ther-
apy, with a primary study outcome of EFS. Secondary outcomes
include correlative laboratory studies, such as PIAs to determine
inhibition of FLT3 phosphorylation. MLL wild-type infants did
not receive lestaurtinib.
PKC412/midostaurin
PKC412/midostaurin in adult leukemia. A phase 2 clinical trial
of midostaurin in 20 adults with relapsed or refractory FLT3-
mutated MDS or AML showed that drug was generally well
tolerated, though 2 patients suffered fatal pulmonary events of
uncertain etiology (115). Peripheral blood blasts decreased by at
least 50% in 14 (70%) of patients, and this result was sustained for
at least 4 weeks in 7 (35%) patients. PIAs were not used in this trial,
but peripheral blasts recovered at early time points demonstrated
inhibition of FLT3 phosphorylation in patients with good clinical
responses.
This was followed by a phase 2B study in 95 adults with
relapsed or refractory AML or those unable to receive conventional
chemotherapy. Patients had wild-type or mutated FLT3 and were
randomly assigned to receive oral midostaurin monotherapy at
either 50 or 100 mg twice daily. Interestingly, 71% of patients with
mutant FLT3 experienced a hematological response with at least
50% reduction in peripheral blasts, whereas only 42% of patients
with wild-type FLT3 demonstrated a clinical response (116). A
phase 1B study combined midostaurin with standard induction
chemotherapy in three different schedules, in patients with newly
diagnosed AML. At tolerable doses of 50 mg twice daily, there was
an 80% complete response (CR) rate in these patients; specifi-
cally, 74% CR rate in FLT3-wild-type patients and 92% CR rate
in FLT3-mutant patients (117). These results provided rationale
for a large, recently completed phase 3 clinical trial of midostaurin
for adult AML with FLT3-mutant leukemia (clinical trial identifier
NCT00651261); results are not yet available1.
PKC412/midostaurin in pediatric leukemia. In pediatrics, a
phase 1/2 clinical trial open in Europe and some U.S. centers is
currently recruiting MLL-r infant ALL and FLT3-mutant AML
patients to receive midostaurin as a single agent, with a primary
outcome of determining the maximally tolerated dose (MTD).
Secondary outcomes include safety/tolerability, PKs, preliminary
efficacy of the drug in these diseases, and laboratory correla-
tives, including evaluation of FLT3 phosphorylation before and
after drug.
AC220/quizartinib
Quizartinib, a small-molecule inhibitor engineered specifically
for FLT3, is incredibly potent and selective compared to the
previous “first-generation” FLT3 inhibitors, with low nanomo-
lar concentrations of quizartinib achieving inhibition in vitro
(118, 119).
AC220/quizartinib in adult leukemia. In a phase 1 adult study,
76 patients with relapsed or refractory AML received quizartinib
monotherapy (120). Hematological responses were seen in 53% of
patients with FLT3-ITD mutations, and PIAs revealed near-total
inhibition of FLT3 phosphorylation in nearly all cases. Subse-
quently, a phase 2 study of relapsed/refractory AML patients,
all containing ITD mutations, recently completed accrual, and
results were presented in abstract form at the 2012 American Soci-
ety of Hematology (ASH) meeting (121, 122). As monotherapy,
quizartinib impressively induced a CR or a CR with incomplete
blood count recovery (CRi) in 9 of 17 patients (53%). Ongoing
adult studies are now evaluating quizartinib in combination with
chemotherapy (NCT01390337)1.
AC220/quizartinib in pediatric leukemia. The Therapeutic
Advances in Childhood Leukemia and Lymphoma (TACL) con-
sortium recently completed a pilot study of quizartinib in com-
bination with cytarabine and etoposide, in pediatric patients
with MLL-r ALL or relapsed/refractory AML. Chemotherapy was
administered on days 1–5 and oral quizartinib was given days
7–28, for up to two courses of therapy. PIAs were obtained
to determine biological efficacy of FLT3 inhibition. Preliminary
results were presented at the 2013 annual ASH conference and
showed good tolerability of drug (123). The correlative PIA assays
demonstrated near-total (>99%) inhibition of FLT3 phospho-
rylation after quizartinib. Importantly, four of six patients with
FLT3-ITD-mutant AML achieved a CR or CRi and the other
two ITD patients had stable disease. These results support fur-
ther testing of quizartinib in pediatric leukemia, particularly in
FLT3-ITD-mutant AML.
1www.clinicaltrials.gov (accessed on July, 2014).
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Sorafenib
Sorafenib in adult leukemia. Three phase 1 trials with sorafenib
in adults with relapsed/refractory AML have been published to
date. The first study treated 16 patients and found a hematological
response (>50% reduction in peripheral or BM blasts) in patients
with ITD mutations but not in those with wild-type FLT3 (124).
The second study included one patient with an ITD mutation who
achieved a CR with sorafenib alone (125). In the third study, the
best response was stable disease in 11 of 15 patients, but 2 of these
11 were the only patients with ITD mutations (126).
A phase 1/2 adult study evaluated 10 relapsed AML patients
with sorafenib in the dose-finding phase, and then treated 51
newly diagnosed AML patients with a combination of sorafenib,
cytarabine, and idarubicin (127). PIAs demonstrated complete
inhibition of FLT3 phosphorylation. Impressively, 38 (75%) of
all patients achieved a CR, and all patients with ITD mutations
achieved a CR or a CRi. One year-OS rate for all patients was 74%.
A phase 2 German study randomized elderly AML patients to
receive placebo or sorafenib, followed by cytarabine (128). No dif-
ferences in EFS or OS were noted, but this study was limited by the
patient population and the relatively small number of ITD-positive
patients (28 of 197 or 14%).
Sorafenib in pediatric leukemia. Recent early phase pediatric
clinical trial reports with sorafenib appeared promising. Inaba
et al. published results from a pilot group of 12 patients with
relapsed/refractory AML. Patients received sorafenib in combina-
tion with clofarabine and cytarabine in the following manner: oral
sorafenib on days 1–7, sorafenib plus IV clofarabine/cytarabine on
days 8–12, and single-agent sorafenib on days 13–28 if tolerated
(111). Grade 3 dose limiting toxicity (DLT) of hand–foot skin
reaction was reported at a dose of 200 mg/m2, thus 150 mg/m2
was subsequently used and well tolerated. Five of five patients
with ITD mutations achieved a CR or CRi, and three of seven
patients with wild-type FLT3 also achieved a CR. In vitro inhibi-
tion of FLT3 downstream signaling protein phosphorylation was
demonstrated in most of these patient samples upon treatment
with sorafenib. Interestingly, conversion of sorafenib to its active
metabolite, sorafenib N-oxide, was three to four times higher in
children than previously reported in healthy adult and adults with
leukemia. Although this may have contributed to increased non-
DLT skin reactions seen in children, the active metabolite is also a
more potent inhibitor of FLT3-ITD (111).
Watt and Cooper described three case reports of pediatric
relapsed/refractory AML that achieved sustained remissions with
sorafenib in combination with chemotherapy. Significant toxici-
ties were noted in two of three patients, but efficacy was demon-
strated in each case. Sorafenib combination therapy served as
a bridge to transplant in one of these cases, a 7-year old male
with ITD-mutant AML, and that patient remains in remission
21 months post-transplant (129). Finally, a COG phase 1 consor-
tium trial at the NCI investigated single-agent sorafenib in refrac-
tory solid tumors or leukemia. The MTD for solid tumors and
leukemia are 150 and 200 mg/m2 twice daily, respectively. Eleven
leukemia patients (eight AML and three ALL) were enrolled. Two
AML patients with ITD mutations achieved a CR and went off
study to undergo stem cell transplantation (112).
Given these encouraging results, the current phase 3 COG ran-
domized trial for newly diagnosed AML incorporates sorafenib
for pediatric FLT3-ITD AML. This trial non-randomly assigns
ITD-mutant patients with high allelic ratios (>0.4, as previously
discussed, HR-ITD) to Arm C, which includes sorafenib in addi-
tion to chemotherapy. Simultaneous sorafenib begins immediately
in induction therapy and continues throughout the treatment pro-
tocol. It is recommended for all high-risk patients to receive a stem
cell transplant in first CR, if any suitable donor is available. For
HR-ITD patients, this trial also includes a maintenance phase with
single-agent sorafenib for 1 year, beginning between day 40–80
either after transplant or after finishing chemotherapy.
ASP2215
ASP2215, a promising new small-molecule inhibitor, demon-
strated potent kinase inhibition of FLT3,LTK,ALK,and AXL (130).
Furthermore, ASP2215 inhibited the growth of cell lines express-
ing FLT3-ITD or FLT3-D835-TKD mutations. The same group
also showed that ASP2215 induced complete tumor regression in
MV4;11 xenografts as a single agent (130) and in combination
with chemotherapy (131). ASP2215 is currently being investigated
in adult relapsed/refractory AML with a multi-institutional phase
1/2 trial in the United States (NCT02014558) and a phase 1 trial
in Japan (NCT02181660)1.
OTHER THERAPEUTIC APPROACHES IN FLT3-ACTIVATED LEUKEMIA
Role of HSCT in first remission in patients with FLT3-ITD mutations
The beneficiary role of HSCT in first remission for FLT3-ITD AML
has been controversial, although due to generally poor outcomes in
this cohort with chemotherapy alone, HSCT is rapidly becoming
the standard of care (132, 133). With improved transplant-related
mortality in recent years, the benefit of HSCT in pediatric high-
risk AML has become more apparent. Two recent pediatric reports
show no significant difference in outcomes between high-risk
(including FLT3-ITD patients) and standard-risk AML patients
receiving HSCT in first CR, demonstrating that HSCT abro-
gates the poor outcomes associated with high-risk pediatric AML
(134, 135). The current phase 3 COG randomized trial for newly
diagnosed AML, as mentioned, non-randomly assigns HR-ITD
patients to Arm C with sorafenib. Patients may continue on study
as long as they achieve and maintain remission status (<5% blasts
at end of induction II or better). After intensification I, these
patients may proceed with allogeneic HSCT if any appropriate
donor is available, and if no donor is available, they may receive
another intensification cycle (with ongoing sorafenib). This is not
a randomized design, but the outcomes of these patients compared
to historical controls are hypothesized to show improvement with
HSCT.
Role for maintenance FLT3 inhibitor after hematopoietic stem cell
transplantation
Adult leukemia. There are good data in the adult literature to
suggest a role for sorafenib as maintenance therapy in FLT3-
ITD AML, particularly after HSCT. Several smaller studies of
relapsed adult FLT3-ITD AML post-HSCT reported some CRs
and other good responses with single-agent sorafenib after allo-
geneic HSCT (136–138). A recent retrospective review of 65 FLT3-
ITD AML patients compared single-agent sorafenib efficacy in
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newly relapsed patients who had previously received conventional
chemotherapy versus those who had a prior HSCT (139). In this
series, the patients who had received a prior HSCT achieved longer
remission before treatment failure compared to those receiving
chemotherapy previously (197 versus 136 days, p= 0.0305) and
also achieved “deeper” remissions, with a strikingly 24% of post-
HSCT patient achieving a complete molecular remission (com-
pared to 8% with prior chemotherapy). The authors of this series
and others have proposed a possible immuno-modulatory effect
of sorafenib after transplant in these patients, though a mech-
anism for this effect is not yet elucidated. Ongoing adult clini-
cal trials are studying post-transplant sorafenib in greater detail
(NCT01578109, NCT01398501). Also, a phase 1 study is evaluat-
ing quizartinib as maintenance therapy after allogeneic transplant
in adult AML (NCT01468467), and a phase 2 study is investi-
gating midostaurin as maintenance after allogeneic transplant in
FLT3-ITD adult AML (NCT01883362)1.
Pediatric leukemia. There is limited but promising experience
with post-HSCT sorafenib in pediatric AML. In Seattle, 15 FLT3-
ITD pediatric AML patients received sorafenib post-HSCT: 10
after relapse and 5 prophylactically. Seven of the 10 relapsed
patients remain in a second CR at a median of 12.5 months post
start of therapy, and 4 of the 5 patients given sorafenib prophy-
lactically remain disease-free at a median of 10 months (Pollard,
unpublished data). Interestingly, one patient who received pro-
phylactic sorafenib post-HSCT was discovered to have an ITD-
negative clone at relapse, suggesting clonal evolution. The current
phase 3 COG-AAML1031 trial incorporates maintenance FLT3
inhibitor therapy after transplant. FLT3-ITD patients on this study
will have received sorafenib in pre-HSCT therapy, and upon count
recovery post-HSCT, will resume sorafenib as a single agent until
day 364 post-transplant. Effectiveness of this novel maintenance
FLT3 inhibitor therapy is yet to be determined. Also, the effect of
sorafenib on graft versus host disease, and therefore, potentially
graft versus leukemia effect, is not known. The role of other FLT3
inhibitors, such as quizartinib, after stem cell transplant in FLT3-
activating leukemia has not yet been addressed in the pediatric
population.
CHALLENGES AND FUTURE APPROACH TO FLT3 INHIBITION
FLT3 INHIBITOR RESISTANCE: BOTH CHALLENGE AND VALIDATION OF
FLT3 ADDICTION
Despite promising biological activity in pre-clinical models and
good clinical activity of various FLT3 inhibitors in early phase
clinical trials, effective therapeutic targeting of FLT3 has proved
challenging. Resistance to targeted therapy often develops due
to pharmacokinetic (extrinsic) or pharmacodynamic (intrinsic)
forces. The mechanisms of resistance to FLT3 inhibitors can be
further classified as extrinsic, receptor-intrinsic, or cell-intrinsic
(140). Primary resistance occurs from the onset of treatment, and
secondary resistance occurs at relapse after initial response to FLT3
inhibitors.
Extrinsic mechanisms: pharmacokinetic barriers
Trials with first-generation FLT3 inhibitors showed difficulty
achieving adequate plasma free drug concentrations. Hepatic
CYP3A4-mediated metabolism of midostaurin results in two
metabolites with decreased FLT3-specific activity. Midostaurin
and its metabolites can also induce CYP3A4, resulting in highly
unreliable concentrations of drug (141). Midostaurin must there-
fore be given with caution with other medications affecting
CYP3A4 activity. Lestaurtinib is particularly highly bound to
plasma protein, and competes with anthracyclines for alpha-1
acid glycoprotein binding sites, resulting in decreased free con-
centration of lestaurtinib, and potentially increased anthracycline
toxicity. Also, medications such as azole antifungals can affect the
metabolism of certain FLT3 inhibitors (142).
Cell-intrinsic mechanisms
Activation of alternate pathways and survival signaling. Pri-
mary resistance to FLT3 inhibitors can occur through the activa-
tion and up-regulation of alternate survival signaling pathways.
Anti-apoptotic pathways involving Bcl-x and BCL2 are differen-
tially activated in FLT3-ITD compared to FLT3-wild-type AML
(143). Interestingly, BCL2 is not down-regulated in FLT3-ITD
cells upon FLT3 inhibitor treatment, signifying a mechanism of
primary resistance. Treatment with the BH3 mimetic ABT737
restored sensitivity to FLT3 inhibition, suggesting a role for dual
targeting of FLT3 and BCL2 (144). MV4;11 cells are homozy-
gous for ITD, and upon developing resistance to midostaurin,
demonstrate up-regulation of anti-apoptotic genes MCL-1 and
C-KIT by microarray and PCR compared to parental MV4;11
cells (145). Knapper et al. demonstrated that AML primary cells
show variable cytotoxicity to FLT3 inhibition with midostaurin
or lestaurtinib and retain activation of STAT5 and MAPK path-
ways even with near-complete inhibition of FLT3 phosphorylation
(146). In another investigation,human AML cell lines in prolonged
culture with FLT3 inhibitors were selected for resistant clones, and
sequencing of these clones revealed no secondary TKD mutations.
FLT3 was completely inhibited in these resistant cells, yet the phos-
phorylation and activation of STAT5, AKT, and/or MAPK was
maintained (147). Furthermore, MEK or PI3K inhibition restored
sensitivity of these cells to FLT3 inhibition. Piloto et al. also found
that two of the resistant cell lines had developed new, activating
N-Ras mutations that were not present in the parental sensitive cell
line. Taken together, these reports are supporting in vitro evidence
for the activation of FLT3-independent pathways, promoting cell
survival and proliferation during FLT3 inhibitor therapy.
Another proposed mechanism of resistance involves the FL.
Sato et al. showed that FL levels are significantly higher following
intensive chemotherapy, and are strikingly high in relapsed AML
patients (148). Adding exogenous FL to AML samples in vitro (at
levels similar to that seen in patients) conferred relative resistance
to five different FLT3 inhibitors. This spike of FL after chemother-
apy may therefore represent an obstacle to FLT3 inhibition, and
suggests a role for the development of novel FL inhibitors. Reduc-
ing chemotherapy intensity could attenuate the rise in FL and may
be an important consideration. In another model, investigators
compared the gene-expression profiles of MV4;11 cells resistant
or sensitive to FLT3 inhibitor ABT869 (149). The resistant cells
showed up-regulation of FL and survivin, and up-regulated sur-
vivin led to decreased apoptosis and increased number of cells in
S phase. They propose that an increase in FL in the resistant cells
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caused increased STAT activation, which in turn led to increased
survivin. This group further showed that survivin expression
was directly regulated by activated STAT3. Combining ABT869
with the STAT inhibitor IDRE804 reversed this effect, and the
combination demonstrated therapeutic synergy in vivo.
Microenvironment and stromal protection. Clinical studies with
single-agent FLT3 inhibitors demonstrate good clearance of circu-
lating peripheral blasts, but a marginal or delayed effect on blasts
in the BM, suggesting a protective role of the BM microenviron-
ment. Leukemic stem cells (LSC), like normal hematopoietic stem
cells, reside in stromal “niches” with specialized conditions for
optimal growth and survival (150). Sequestered in these niches,
it is hypothesized that LSCs may evade chemotherapy or targeted
therapy-induced cell death. Interestingly, in stroma-like condi-
tions in vitro, FLT3-ITD AML blasts become resistant to FLT3
inhibitor effects, and in fact demonstrate expansion (151, 152).
CXCR4 and its ligand, SDF-1, are important regulators of stro-
mal/leukemia cell interactions (153, 154). FLT3 and its ligand FL
have been shown to modulate surface CXCR4 expression, which is
up-regulated in FLT3-ITD AML patient samples (155, 156). Sub-
sequently, pre-clinical models have shown that CXCR4 inhibition
enhances the sensitivity of FLT3-ITD AML cells to FLT3 inhibi-
tion (157, 158). An ongoing phase 1 trial in adults is investigating
the combination of CXCR4 inhibitor AMD3100 (Plerixafor) and
sorafenib in relapsed/refractory FLT3-ITD AML (NCT00943943).
It has been demonstrated that Plerixafor enhances the response
of MLL-r ALL cells to FLT3 inhibition in xenografts, suggesting
that this dual targeting may prove useful in this high-risk subset
of pediatric leukemia patients (159).
Receptor-intrinsic mechanisms
Acquired point mutations. In BCR-ABL leukemia, the selection
of clones that harbor mutations in the ATP-binding pocket and
prevent the binding of imatinib is the most common cause of drug
resistance (160). Likewise, the development of TKD point muta-
tions at relapse after FLT3 inhibitor therapy is well described, and
is a significant mechanism of secondary resistance in FLT3-ITD
AML patients (161). This phenomenon is compelling evidence
that FLT3-ITD represents a driver mutation in AML, and that the
ITD activating mutation can render a state of “oncogene addic-
tion” in this disease. Prior to reports of acquired mutations in
patient samples, forced resistance to FLT3 inhibitors in vitro pre-
dicted the development of acquired TKD mutations at certain
key residues (162, 163). Many of these have since been confirmed
in patients, and Table 2 summarizes acquired point mutations
that have been described after FLT3 inhibitor therapy. The first
case report described a novel FLT3-TKD mutation N676K, dis-
covered at relapse in an FLT3-ITD AML patient after midostau-
rin monotherapy (164). 32D cells transfected with ITD-N676K
FLT3 confirmed in vitro resistance to midostaurin, relative to
cells transfected with FLT3-ITD. The second report described a
FLT3-ITD-positive, BCR-ABL-negative CML patient in blast cri-
sis, who acquired the mutation A848P at relapse after a 9-month
response to alternating therapy with sunitinib and sorafenib (165).
Ba/F3 cells with ITD-A848P FLT3 were resistant to both sunitinib
and sorafenib, but maintained sensitivity to midostaurin. Neither
Table 2 | Acquired point mutations in FLT3-ITD patients after FLT3
inhibitor therapy.
Mutation Disease Therapy Reference Validated
in vitro
N676K AML PKC412 Heidel et al. (164) 32D
A848P CMML
Relapsed
blast crisis
Sunitinib and
sorafenib
von Bubnoff et al.
(165)
Ba/F3
F691L AML AC220 Smith et al. (161) Ba/F3
AML AC220 Albers et al. (167) Ba/F3
AML
(pediatric)
Sorafenib Baker et al. (168)
D835Y AML AC220 Smith et al. (161) Ba/F3
AML Sorafenib Man et al. (169)
AML
(pediatric)
Sorafenib Baker et al. (168)
D835V AML AC220 Smith et al. (161)
D835F AML AC220 Smith et al. (161)
D835H AML Sorafenib Man et al. (169) Ba/F3
AML
(pediatric)
Sorafenib Baker et al. (168)
D651G AML Sorafenib Zhang et al. (170)
G619C AML Sorafenib Zhang et al. (170)
I687F AML Sorafenib Zhang et al. (170)
E858K AML Sorafenib Zhang et al.(170)
mutation was detected prior to FLT3 inhibitor therapy. Additional
acquired mutations are likely to emerge, based on screening in vitro
models, such as the highly resistant Y842C mutation (166).
A recent report evaluated paired pre-treatment and relapsed
samples from eight adult FLT3-ITD AML patients treated with
quizartinib monotherapy, all of which relapsed after initial good
marrow responses (161). Using single molecule real-time (SMRT)
sequencing, the ITD alleles were analyzed and all eight patients
had developed additional point mutations in the kinase domain
at relapse that were not detected pre-treatment. Four patients
had developed polyclonal resistance with multiple point muta-
tions, validating the significant selective pressure of quizartinib on
these leukemic clones. In this report, TKD mutations in patients
were confined to residues F691 and D835. In vitro cell-based
assays containing these mutations confirmed resistance to quizar-
tinib, and demonstrated cross-resistance to sorafenib (161). Other
reports have identified or confirmed TKD mutations after FLT3
inhibitor therapy with quizartinib (167) or sorafenib (168–170).
Baker et al. described three pediatric AML patients who par-
tially responded to sunitinib treatment after developing sorafenib-
mediated TKD mutations D835H, D835Y, or F691L. However,
two of these three patients had expansion of the D835Y pop-
ulation while on sunitinib, and this mutation was polyclonal,
present on both ITD-positive and ITD-negative alleles (168).
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Interestingly, although many studies report that TKD mutations
are not detected prior to FLT3 inhibitor therapy, emerging evi-
dence suggests these TKD mutations may be present in a tiny
sub-clone at pre-treatment, which is not easily detectable, but is
selected for over time with FLT3 inhibitor therapy. Man et al.
expanded LIC from pre-treatment patient samples in NOD/SCID
mice. In these xenografts, D835Y-positive clones were expanded,
which had only been detected in the paired post-sorafenib patient
samples at relapse (169).
The patterns of TKD mutations and drug resistance are non-
overlapping, suggesting that combinations of FLT3 inhibitors may
partially overcome the development of resistance (171). Type I
FLT3 inhibitors, lestaurtinib and midostaurin, bind to the active
formation of the FLT3 receptor, whereas type II inhibitors bind to
the inactive formation (172). Also, not all acquired TKD muta-
tions confer resistance in the same manner. Ba/F3 cells with
D835H/Y demonstrate IL-3-independent growth and increased
STAT5 phosphorylation, consistent with reports that D835 muta-
tions are primary transforming events (173). Ba/F3 cells with
FLT3-F691L are not transformed, suggesting that F691 mutations
are secondary events and confer resistance by interfering with drug
binding. Most FLT3 inhibitors make direct contact with residue
F691 (166); although sunitinib does not, which could explain its
conserved sensitivity in F691 mutants (168). In contrast, much
evidence suggests that type II inhibitors quizartinib and sorafenib
are inactive against D835 mutations, likely due to the mutant’s
stabilization of the FLT3 receptor in the active formation. Baker
et al. showed that cells with FLT3-ITD-D835Y mutant were par-
tially sensitive to midostaurin, which has type I inhibitor activity.
However, the relatively lower potency of the first-generation type I
inhibitors limit their efficacy as single agents. The next-generation
FLT3 inhibitor crenolanib has shown promising efficacy against
FLT3-ITD-D835Y AML samples, and is currently in a phase 2 clin-
ical trial for adult AML (174). Taken together, these data argue for
personalized selection and careful consideration of FLT3 inhibitor
therapy in FLT3-ITD patients, and close monitoring for the emer-
gence of TKD-mutant clones, which may be more susceptible to
different FLT3 inhibitors.
Up-regulation of FLT3 receptor. Studies have shown increased
expression of FLT3 itself in AML blasts during treatment with
midostaurin (106) or lestaurtinib (113). It is not definitively
known whether this observation represents a feedback loop that
can act as a mechanism of resistance.
CLONAL EVOLUTION OF THE LEUKEMIC STEM CELL
Increasing evidence suggests that small populations of cancer stem
cells can evade anti-neoplastic induced cytotoxicity (175, 176).
Likewise in AML, genome-wide sequencing of paired diagnostic-
relapsed samples reveal that multiple sub-clones are usually
present at diagnosis, which have evolved from a “founding clone,”
synonymous with the LSC. At relapse, a dominant sub-clone
emerges, either because the founding clone has gained additional
mutations or a particular sub-clone has survived initial therapy
(177). The latter mechanism of relapse is likely to be shaped
by whatever remission-inducing therapy the patient has received.
In vitro comparison of FLT3 inhibitor cytotoxicity in diagnostic
and relapsed FLT3-ITD patient samples demonstrate that FLT3
inhibitor therapy is relatively less cytotoxic at diagnosis, despite
adequate inhibition of FLT3 phosphorylation. This suggests that
at diagnosis in FLT3-ITD AML, the dominant clone may not always
be reliant on FLT3 signaling. In contrast, relapsed AML cells with
a higher ITD allelic burden are more sensitive to FLT3 inhibitors,
suggesting that an ITD dominant clone is more likely to emerge at
relapse (178).
In order for a targeted therapy to eradicate disease, the tar-
get itself must be present in the cancer stem cell, and it remains
controversial whether FLT3-ITD mutations are present in the
LSC. FLT3-ITD mutations are present in CD34+38− leukemic
initiating cells (38) and confer an engraftment advantage over
non-FLT3-ITD AML in a xenograft model (179), suggesting that
ITD mutations are present in the LSC. However, ITD mutations
occur as both early and late “hits” in patients. In some cases, ITD
mutations were present at diagnosis and lost at relapse, and in
other patients, ITD mutations were acquired at relapse, providing
evidence the ITD mutation occurred in a sub-clone and not the
LSC (180, 181). Determining at which stage the ITD mutation
arises has significant clinical implications regarding the strategic
use and timing of FLT3 inhibitor therapy in AML.
FUTURE APPROACHES
Careful treatment strategies are needed to increase the effi-
cacy of targeted FLT3 therapy and decrease the development
of resistance. The current approach to increasing efficacy has
been to develop novel FLT3 inhibitors with increased potency
and higher selectivity. However, as seen with quizartinib, these
newer agents may increase the development of intrinsic resis-
tance. Combining FLT3 inhibitors with chemotherapy improves
responses, but does not preclude the development of resistance.
When acquired mutations develop in BCR-ABL positive dis-
ease, the approach has been to switch to a different targeted
agent. This approach could be taken in FLT3-ITD AML and
would entail close monitoring for the development of TKD
mutations while on FLT3 inhibitor therapy. Another approach
could involve combining multiple FLT3 inhibitors that bind to
different conformations of the receptor, in an attempt to pre-
vent resistance. As discussed, some reports suggest that FLT3
inhibitors may be more effective in relapsed disease or in dis-
ease with a higher ITD allelic burden, and it might be prudent
to reserve targeted therapy for those scenarios. Also, when FLT3
inhibitors are used in combination with chemotherapy, it may
be possible to decrease the intensity of conventional chemother-
apy drugs, and this might have the added benefit of lessening
the FL surge demonstrated during more intensive chemotherapy.
The development of a novel FL-inhibiting therapy would likely
be synergistic with FLT3 inhibition. Perhaps, the most promis-
ing approach would be the dual inhibition of FLT3 and other
pro-survival pathways, such as PI3K/AKT/mTOR, JAK/STAT5,
or RAS/Raf/MEK/ERK inhibitors, and clinical trials investigat-
ing novel dual inhibitors (NCT02055781) or combining kinase
inhibitors (NCT00819546) are underway1. Finally, combining
FLT3 and CXCR4 inhibitors could overcome stromal protection
of FLT3-activated leukemia cells and could be additive to any of
the approaches above.
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SUMMARY
The identification of FLT3 aberrancies in high-risk subsets of
leukemia patients was discovered two decades ago, and much has
been learned about the biology, clinical implications, and target-
ing possibilities. It remains controversial whether FLT3-ITD is an
initiating event in leukemogenesis, yet the striking development of
intrinsic resistance with FLT3 inhibitor therapy supports its role
as one of the most meaningful cooperating events in the devel-
opment of human AML (177). Both adult and pediatric clinical
trials continue to investigate different FLT3 inhibitors in combina-
tion with chemotherapy in patients with FLT3-mutant AML. Also,
in MLL-r infant ALL, wild-type FLT3 overexpression portends an
especially poor prognosis, and FLT3 inhibitor therapy in these
patients is being investigated in a phase 3 clinical trial through the
COG. In the meantime, resistance to FLT3-targeted therapy poses
a significant challenge in the treatment of FLT3-activated leukemia
patients.
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